First in human dose calculation of a single-chain bispecific antibody targeting glioma using the MABEL approach

BACKGROUND: First-in-human (FIH) clinical trials require careful selection of a safe yet biologically relevant starting dose. Typically, such starting doses are selected based on toxicity studies in a pharmacologically relevant animal model. However, with the advent of target-specific and highly act...

Descripción completa

Detalles Bibliográficos
Autores principales: Schaller, Teilo H, Snyder, David J, Spasojevic, Ivan, Gedeon, Patrick C, Sanchez-Perez, Luis, Sampson, John H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254109/
https://www.ncbi.nlm.nih.gov/pubmed/32273346
http://dx.doi.org/10.1136/jitc-2019-000213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254109/
https://www.ncbi.nlm.nih.gov/pubmed/32273346
http://dx.doi.org/10.1136/jitc-2019-000213

Ejemplares similares